A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate …
MP Kolinsky, P Rescigno, D Bianchini, Z Zafeiriou… - Annals of oncology, 2020 - Elsevier
Background Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …
[HTML][HTML] A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer
Background Although androgen receptor-targeted agents prolong the lives of patients with
metastatic prostate cancer, patients develop therapy resistance and most ultimately …
metastatic prostate cancer, patients develop therapy resistance and most ultimately …
A phase I, open-label, dose-finding study of GSK2636771, a PI3Kβ inhibitor, administered with enzalutamide in patients with metastatic castration-resistant prostate …
D Sarker, NA Dawson, AM Aparicio, TB Dorff… - Clinical Cancer …, 2021 - AACR
Purpose: In patients with metastatic castration-resistant prostate cancer (mCRPC),
resistance to androgen receptor (AR)-targeted therapies, such as enzalutamide, remains an …
resistance to androgen receptor (AR)-targeted therapies, such as enzalutamide, remains an …
Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without …
Abstract Purpose: PI3K–Akt–mTOR and androgen receptor (AR) signaling are commonly
aberrantly activated in metastatic castration-resistant prostate cancer (mCRPC), with PTEN …
aberrantly activated in metastatic castration-resistant prostate cancer (mCRPC), with PTEN …
[HTML][HTML] Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 ProCAID clinical …
SJ Crabb, G Griffiths, D Dunkley, N Downs, M Ellis… - European Urology, 2022 - Elsevier
Abstract The PI3K/AKT/PTEN pathway is frequently deregulated in metastatic castration-
resistant prostate cancer (mCRPC). ProCAID was a phase 2 trial assessing addition of the …
resistant prostate cancer (mCRPC). ProCAID was a phase 2 trial assessing addition of the …
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
Summary Background The PI3K/AKT and androgen-receptor pathways are dysregulated in
metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN …
metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN …
[HTML][HTML] Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
Abstract Background The phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)
signalling axis and androgen receptor (AR) pathways exhibit reciprocal feedback regulation …
signalling axis and androgen receptor (AR) pathways exhibit reciprocal feedback regulation …
Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: a randomized, placebo-controlled phase II trial …
SJ Crabb, G Griffiths, E Marwood, D Dunkley… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Capivasertib is a pan-AKT inhibitor. Preclinical data indicate activity in metastatic
castration-resistant prostate cancer (mCRPC) and synergism with docetaxel. PATIENTS …
castration-resistant prostate cancer (mCRPC) and synergism with docetaxel. PATIENTS …
LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)
Background PI3K/AKT and androgen receptor (AR) signalling are dysregulated in mCRPC.
PTEN loss (40%-50% of mCRPC) results in activation of AKT, the ipat target, and worse …
PTEN loss (40%-50% of mCRPC) results in activation of AKT, the ipat target, and worse …
Alliance A031201: a phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate …
5008 Background: Androgen receptor (AR) signaling is an important growth mechanism in
mCRPC, providing the rationale for treatment with AR axis inhibitors such as ENZ and AAP …
mCRPC, providing the rationale for treatment with AR axis inhibitors such as ENZ and AAP …
相关搜索
- abiraterone acetate prostate cancer
- pten loss prostate cancer
- capivasertib in combination prostate cancer
- enzalutamide enz prostate cancer
- enzalutamide in combination akt inhibitor
- enzalutamide in combination dose escalation
- dose escalation prostate cancer
- dose escalation akt inhibitor
- akt inhibitor prostate cancer
- enzalutamide in patients pi3kβ inhibitor
- akt blockade combination with abiraterone
- abiraterone acetate capivasertib in combination
- predictive biomarker prostate cancer
- enzalutamide in patients open label
- docetaxel and prednisolone prostate cancer
- placebo pbo prostate cancer